Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers

Journal:

Journal of Clinical Investigation

Published:

2025-08-19

DOI:

10.1172/jci191781

Affiliations:

10

Authors:

17

Go to article

Institutions	Authors	Share
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	14.500000 14.500000	0.85
University of Colorado Denver (CU Denver), United States of America (USA)	1.000000	0.06
Western University (UWO), Canada	1.000000	0.06
Cleveland Clinic, United States of America (USA)	0.500000	0.03

Interested in Immunology?